screen_shot_2014-02-04_at_14

Novo Nordisk appoints chief medical officer

pharmafile | January 30, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, todd hobbs 

Dr Todd Hobbs has been appointed chief medical officer (CMO) for Novo Nordisk in North America.  

In this role Hobbs will focus on the implications of diabetes for the firm and for patients, healthcare professionals and for healthcare systems. 

Hobbs has a specific dedication to the treatment of diabetes that began nearly 25 years ago when he was diagnosed with type 1 diabetes, which intensified with the diagnosis of one of his sons with the same condition at the age of five.

He began his career at Novo Nordisk in 2004 as a field medical scientific director. In 2010, he moved to the in-house position of senior medical director of Diabetes. 

Prior to being named CMO he led Medical Affairs activities for all insulin products and devices at Novo Nordisk.

“At Novo Nordisk, we are intensely focussed on the patient experience and are committed to finding solutions to help those living with diabetes achieve their goals,” said Anne Phillips, senior VP, clinical medical & regulatory affairs for Novo Nordisk.

“As a patient and parent of a child living with diabetes, Todd brings a unique perspective and shares our passion for patient centricity.”

Related Content

CHMP recommends Novo Nordisk’s Awiqli for diabetes treatment

Novo Nordisk has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for …

Almirall licenses Novo Nordisk’s anti-IL-21 monoclonal antibody for dermatology treatment

Almirall has announced that it has entered into an exclusive license agreement with Novo Nordisk …

Novo Nordisk shares positive results from COMBINE 3 phase 3a trial

Novo Nordisk has shared topline results from the COMBINE 3 phase 3a trial of once-weeklly …

Latest content